Education
About Us
Working with TipRanks
Follow Us
Idorsia Ltd (CH:IDIA)
:IDIA
Top Page
Idorsia Ltd
(IDIA)
Select Model
Select Model
Rating:44Neutral
Price Target:
CHF3.50
▼(-9.33% Downside)
Idorsia Ltd's overall stock score is primarily impacted by its weak financial performance, characterized by significant losses and high leverage. Technical analysis shows some short-term bullish trends, but momentum indicators suggest caution. The valuation is unattractive due to negative earnings and lack of dividends, further weighing down the score.
Positive Factors
Revenue Growth
The significant revenue growth indicates strong demand for Idorsia's products, suggesting effective market penetration and potential for future expansion.
Strategic Partnerships
Partnerships enhance financial resources and expand research capabilities, providing a durable competitive advantage and potential for new market opportunities.
Product Innovation
Idorsia's emphasis on innovation in drug discovery positions it well to address unmet medical needs, potentially leading to sustainable competitive advantages.
Negative Factors
High Leverage
High leverage poses a risk to financial stability, limiting flexibility and increasing vulnerability to economic downturns, which could impact long-term growth.
Negative Cash Flow
Persistent negative cash flow indicates challenges in sustaining operations without external financing, which can hinder long-term financial health.
Profitability Challenges
Ongoing profitability issues suggest operational inefficiencies and cost structure problems, potentially affecting long-term viability and investor confidence.
Idorsia Ltd (IDIA) vs. iShares MSCI Switzerland ETF (EWL)
Market Cap
CHF890.38M
Dividend YieldN/A
Average Volume (3M)2.48M
Price to Earnings (P/E)―
Beta (1Y)2.47
Revenue Growth229.23%
EPS Growth63.47%
CountryCH
Employees636
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-0.28
Shares Outstanding249,739,000
10 Day Avg. Volume2,649,008
30 Day Avg. Volume2,478,790
Financial Highlights & Ratios
PEG Ratio0.04
Price to Book (P/B)-0.12
Price to Sales (P/S)1.33
P/FCF Ratio-0.40
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
CHF5.25Price Target Upside36.01% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Idorsia Ltd Business Overview & Revenue Model
Company DescriptionIdorsia Ltd, a biopharmaceutical company, discovers, develops, and commercializes drugs for unmet medical needs in Switzerland. The company has a clinical development pipeline that cover various therapeutic areas, including CNS, cardiovascular, and immunological disorders, as well as orphan diseases. Idorsia Ltd has a collaboration agreement with Janssen Biotech Inc. to jointly develop and commercialize aprocitentan and its derivative compounds or products; license agreement with Mochida Pharmaceutical for the supply, co-development, and comarketing of daridorexant; and Hoffman-La Roche Inc. to develop and market compounds in the field of cancer immunotherapy. It also has a collaboration with Antares Pharma, Inc. for the development of a self- administered drug device product for Selatogrel; and Neurocrine Biosciences, Inc. to develop and commercialize ACT-709478, which is in Phase II clinical trial for the treatment of epilepsy. The company was incorporated in 2017 and is headquartered in Allschwil, Switzerland.
How the Company Makes MoneyIdorsia generates revenue through the commercialization of its pharmaceutical products, which includes sales of its approved therapies. Additionally, the company engages in strategic partnerships and collaborations with other pharmaceutical firms, which can provide upfront payments, milestone payments, and royalties on sales of partnered products. These partnerships not only enhance Idorsia's financial resources but also expand its research capabilities and market reach. Furthermore, the company may receive funding through grants or investments aimed at supporting its research and development efforts in new drug discoveries.
Idorsia Ltd Earnings Call Summary
Earnings Call Date:Jul 30, 2025
(Q2-2025)
| % Change Since: |
Next Earnings Date:Feb 26, 2026
Earnings Call Sentiment Positive
The earnings call highlighted strong growth in QUVIVIQ sales, significant improvements in financial metrics, and promising pipeline developments. However, challenges remain with flat U.S. sales and uncertainties in regulatory processes. Overall, positive developments and strategic advancements contribute to a cautiously optimistic outlook.Q2-2025 Updates
Positive Updates
QUVIVIQ Sales Surge
QUVIVIQ net sales in H1 2025 more than doubled compared to last year, rising from CHF 23 million to CHF 56 million, showcasing strong commercial traction and growing demand.
Significant Operating Improvement
Improvement in non-GAAP operating results from negative CHF 170 million to negative CHF 15 million, driven by financial discipline and increased sales.
Strategic Partnerships and Approvals
Secured new partnerships and approvals, including QUVIVIQ's approval in China with Simcere, contributing to the extension of Idorsia's cash runway to the end of 2026.
Positive Financial Metrics
Net revenue of CHF 130 million includes CHF 58 million from total QUVIVIQ product sales, a significant increase compared to CHF 24 million in H1 2024.
Pipeline Advancements
Advancements in the pipeline with new data for lucerastat supporting further Phase III investigation, and Phase I study for C. diff vaccine showing positive results.
Negative Updates
Flat U.S. Sales
QUVIVIQ sales in the U.S. remained relatively flat despite significant reduction in sales and marketing costs, with a slight decline in sales.
Uncertainty in Descheduling Process
The descheduling process for the DORA class in the U.S. remains uncertain, with no clear timeline for FDA and DEA processes.
Financial Loss
Guidance indicates a non-GAAP EBIT loss of CHF 100 million and a U.S. GAAP EBIT loss of CHF 55 million, although improved from previous periods.
Company Guidance
In the Idorsia Half Year 2025 Financial Results Webcast and Conference Call, the company provided an optimistic outlook for its future performance. The guidance reiterated the goal of achieving commercial profitability in 2026 and overall profitability by the end of 2027. Key metrics highlighted include a significant growth in QUVIVIQ net sales, which more than doubled from CHF 23 million to CHF 56 million in the first half of 2025. The non-GAAP operating results improved dramatically, from a loss of CHF 170 million to a loss of CHF 15 million. The company's cash runway was extended to the end of 2026, securing further financial stability. Additionally, Idorsia updated its guidance for the partner-led business due to higher milestone payments, leading to an overall non-GAAP EBIT loss of CHF 100 million and a U.S. GAAP EBIT loss of CHF 55 million for 2025. These developments position Idorsia on a solid path to achieving its strategic and financial objectives.Idorsia Ltd Financial Statement Overview
Summary
Idorsia Ltd faces significant financial challenges, marked by consistent losses and high leverage. The company's negative profitability metrics and cash flow issues indicate operational inefficiencies. Despite some improvements in cash flow, the overall financial health remains strained with high debt levels and negative equity.Income Statement
Idorsia Ltd's revenue has seen fluctuations with a noticeable decline of 26.19% from 2023 to 2024. The company consistently reports negative EBIT and net income, indicating ongoing operational challenges. The negative gross profit margin in 2024 suggests cost structure issues. Overall, the company struggles with profitability, reflected in the negative margins.40
Negative
Balance Sheet
The balance sheet shows a negative stockholders' equity, which raises concerns about financial stability. The debt-to-equity ratio is not calculable due to negative equity, but the high total debt level is a potential risk. The equity ratio is negative, indicating that liabilities exceed assets, which is concerning for investors.30
Negative
Cash Flow
Operating cash flow remains negative, indicating challenges in generating cash from operations. However, there is a positive trend in free cash flow from 2023 to 2024, though it remains negative. The free cash flow to net income ratio is not favorable, reflecting difficulties in managing cash effectively.45
Neutral
| Breakdown | TTM | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 217.23M | 112.51M | 152.39M | 97.10M | 35.35M | 71.76M |
| Gross Profit | 107.06M | -67.08M | 145.24M | 90.84M | 17.32M | -309.32M |
| EBITDA | -51.61M | -319.49M | -254.55M | -783.09M | -588.84M | -420.64M |
| Net Income | -133.26M | -263.76M | -297.92M | -827.90M | -634.60M | -445.12M |
Balance Sheet | ||||||
| Total Assets | 498.01M | 505.89M | 500.00M | 904.18M | 1.48B | 1.44B |
| Cash, Cash Equivalents and Short-Term Investments | 82.16M | 124.36M | 157.82M | 476.32M | 1.04B | 1.01B |
| Total Debt | 1.30B | 1.26B | 1.20B | 1.23B | 1.16B | 637.99M |
| Total Liabilities | 1.64B | 1.72B | 1.47B | 1.57B | 1.38B | 849.88M |
| Stockholders Equity | -1.14B | -1.21B | -968.72M | -660.96M | 104.20M | 585.48M |
Cash Flow | ||||||
| Free Cash Flow | -261.77M | -373.23M | -638.69M | -886.17M | -620.83M | -373.95M |
| Operating Cash Flow | -250.65M | -370.23M | -629.30M | -859.11M | -589.89M | -364.67M |
| Investing Cash Flow | -4.84M | 305.06M | 632.61M | 743.90M | -53.26M | -607.13M |
| Financing Cash Flow | 91.58M | 26.11M | -197.00K | 162.31M | 604.15M | 850.08M |
Idorsia Ltd Technical Analysis
Positive
3.86
Price Trends
3.61
Positive
3.35
Positive
2.43
Positive
Market Momentum
0.07
Negative
64.90
Neutral
85.66
Negative
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For CH:IDIA, the sentiment is Positive. The current price of 3.86 is above the 20-day moving average (MA) of 3.30, above the 50-day MA of 3.61, and above the 200-day MA of 2.43, indicating a bullish trend. The MACD of 0.07 indicates Negative momentum. The RSI at 64.90 is Neutral, neither overbought nor oversold. The STOCH value of 85.66 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for CH:IDIA.
Idorsia Ltd Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
74 Outperform | $285.44M | 11.94 | ― | ― | 744.64% | ― | |
73 Outperform | CHF568.22M | 7.80 | ― | ― | 58.51% | ― | |
61 Neutral | CHF1.14B | ― | -7.82% | ― | 104.01% | 33.25% | |
54 Neutral | $129.20M | -1.97 | -49.86% | ― | -100.00% | 14.45% | |
53 Neutral | $163.05M | -2.38 | -301.13% | ― | -56.85% | -186.55% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
44 Neutral | CHF890.38M | -5.36 | ― | ― | 229.23% | 63.47% |
* Healthcare Sector Average
CH:IDIA
Idorsia Ltd
3.85
2.34
155.31%
CH:MOLN
Molecular Partners AG
3.28
-1.61
-33.03%
CH:BSLN
Basilea Pharmaceutica
51.50
10.40
25.30%
CH:KURN
Kuros Biosciences
29.96
8.36
38.70%
CH:NWRN
Newron Pharmaceuticals SpA
20.20
12.48
161.66%
CH:SANN
Santhera Pharmaceuticals Holding
12.42
2.53
25.58%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.